• 1
    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer. N Engl J Med 1996; 334: 16.
  • 2
    Markman M. Prognostic factors in salvage therapy of ovarian cancer. Ann Oncol 1997; 8: 9378.
  • 3
    Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer. A multivariate analysis of 704 patients. Ann Oncol 1997;8: 9638.
  • 4
    Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J Clin Oncol 1995; 13: 177785.
  • 5
    Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 98793.
  • 6
    Muggia FM, Safra T, Groshen S, Jeffers S, Roman L, Tan M, et al. Pegylated liposomal doxorubicin: antitumor activity in epithelial ovarian cancer or cancers of peritoneal origin. Oncology 1997; 11: 3844.
  • 7
    Vaage J, Donovan D, Mayhew E, Abra R, Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993; 72: 37615.
  • 8
    Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 1998; 4: 499505.
  • 9
    Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 6539.
  • 10
    Ovarian Cancer Meta-Analysis Project: Cyclophosphamide, doxorubicin, and cisplatin chemotherapy for ovarian carcinoma. A meta-analysis. J Clin Oncol 1991; 9: 166874.
  • 11
    Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy in ovarian carcinoma. Obstet Gynecol 1992; 80: 95460.
  • 12
    A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 72632.
  • 13
    Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 23953.
  • 14
    Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 154551.
  • 15
    Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992; 10: 5134.
  • 16
    Miller RG Jr. Survival analysis. New York: John Wiley & Sons, 1981: 51.
  • 17
    Pike MC. Contribution to the discussion on the paper by R. Peto and J. Peto, “Asymptotically efficient rank invariant procedures.” J R Stat Soc A 1972; 135: 2013.
  • 18
    Berry G, Kitchin RM, Mock PA. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 1991; 10: 74955.
  • 19
    Lawless JF. Statistical models and methods for lifetime data. New York: John Wiley & Sons, 1982: 7.2.12.
  • 20
    Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963; 58: 690700.
  • 21
    Safra T, Jeffers S, Groshen S, Uziely B, Roman L, Muderspach L, et al. Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): results from three consecutive Phase I/II studies [abstract 1248]. Proc Am Soc Clin Oncol 1997; 16: 349a.
  • 22
    Gordon AN, Hainsworth J, Moore M, Weissman C, Wolin E, Kosty M, et al. Doxil® (doxorubicin HCl liposome injection) in the treatment of patients with refractory advanced epithelial carcinoma [abstract 1345]. Proc Am Soc Clin Oncol 1999; 17: 349a.
  • 23
    Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore M, LaCave AJ, et al. Interim analysis of a Phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer [abstract 1504]. Proc Am Soc Clin Oncol 2000; 19: 380a.
  • 24
    Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997: 15: 130917.
  • 25
    Garcia A, Muggia FM. Activity of anthracyclines in refractory ovarian cancer: recent experience and review. Cancer Invest 1997; 15: 32934.
  • 26
    du Bois A, Luck HJ, Bauknecht T, Meier W, Richter B, Kuhn W, et al. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a Phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 1999; 17: 4651.
  • 27
    Klein P, Hamilton A, Lyass O, Hochster H, Speyer J, Sorich J, et al. Phase I studies of Doxil combined with cisplatin: efficacy in epithelial ovarian and fallopian tube cancers [abstract 1623a]. Proc Am Soc Clin Oncol 2000; 19: 410a.
  • 28
    Hamilton A, Hochster H, Rosenthal M, Chachoua A, Sorich J, Cahr M, et al. Continuous infusion topotecan (TP-CI) and Doxil (Dx): a Phase I study of dual topoisomerase inhibition [abstract 787]. Proc Am Soc Clin Oncol 2000; 200a.